NS Pharma takes on Sarepta as FDA approves DMD drug

The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival.

Roche snaps up ex-US rights to Sarepta's DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal.

Solid Bio hit as FDA slaps clinical hold on DMD gene therapy

Roche joins others in dropping myostatin inhibitor for DMD

NS Pharma steals a march on Sarepta with DMD drug

FDA says no to Sarepta's golodirsen, blocking bid to expand ...